Literature DB >> 12709357

Use of high-performance liquid chromatography to study the pharmacokinetics of colistin sulfate in rats following intravenous administration.

Jian Li1, Robert W Milne, Roger L Nation, John D Turnidge, Timothy C Smeaton, Kingsley Coulthard.   

Abstract

The pharmacokinetics of colistin was investigated using specific high-performance liquid chromatography (HPLC) to measure the concentrations of colistin and colistin A and B in plasma and urine in five rats after administration of an intravenous bolus of 1 mg of colistin sulfate/kg of body weight. There were differences in the pharmacokinetic behaviors of unbound colistin A and B. This is the first report of the use of HPLC to study the pharmacokinetics of colistin and its two major components.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12709357      PMCID： PMC153303          DOI： 10.1128/AAC.47.5.1766-1770.2003

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  24 in total

Review 1.  A ten year review of colomycin.

Authors:  J M Littlewood; C Koch; P A Lambert; N Høiby; J S Elborn; S P Conway; R Dinwiddie; F Duncan-Skingle
Journal:  Respir Med       Date:  2000-07       Impact factor: 3.415

Review 2.  Surveillance of antibiotic resistance in European ICUs.

Authors:  H Hanberger; D Diekema; A Fluit; R Jones; M Struelens; R Spencer; M Wolff
Journal:  J Hosp Infect       Date:  2001-07       Impact factor: 3.926

3.  A simple method for the assay of colistin in human plasma, using pre-column derivatization with 9-fluorenylmethyl chloroformate in solid-phase extraction cartridges and reversed-phase high-performance liquid chromatography.

Authors:  J Li; R W Milne; R L Nation; J D Turnidge; K Coulthard; D W Johnson
Journal:  J Chromatogr B Biomed Sci Appl       Date:  2001-09-25

4.  Multidrug resistance in Gram-negative bacteria.

Authors:  K Poole
Journal:  Curr Opin Microbiol       Date:  2001-10       Impact factor: 7.934

5.  The pharmacokinetics of colistin in patients with cystic fibrosis.

Authors:  M D Reed; R C Stern; M A O'Riordan; J L Blumer
Journal:  J Clin Pharmacol       Date:  2001-06       Impact factor: 3.126

6.  Adverse effects of sodium colistimethate. Manifestations and specific reaction rates during 317 courses of therapy.

Authors:  J Koch-Weser; V W Sidel; E B Federman; P Kanarek; D C Finer; A E Eaton
Journal:  Ann Intern Med       Date:  1970-06       Impact factor: 25.391

7.  Isolation and structural characterization of colistin components.

Authors:  J A Orwa; C Govaerts; R Busson; E Roets; A Van Schepdael; J Hoogmartens
Journal:  J Antibiot (Tokyo)       Date:  2001-07       Impact factor: 2.649

8.  Hyphenated liquid chromatographic method for the determination of colistin residues in bovine tissues.

Authors:  D Decolin; P Leroy; A Nicolas; P Archimbault
Journal:  J Chromatogr Sci       Date:  1997-12       Impact factor: 1.618

Review 9.  The clinical use of colistin in patients with cystic fibrosis.

Authors:  P Beringer
Journal:  Curr Opin Pulm Med       Date:  2001-11       Impact factor: 3.155

10.  Stability of colistin and colistin methanesulfonate in aqueous media and plasma as determined by high-performance liquid chromatography.

Authors:  Jian Li; Robert W Milne; Roger L Nation; John D Turnidge; Kingsley Coulthard
Journal:  Antimicrob Agents Chemother       Date:  2003-04       Impact factor: 5.191
View more
  66 in total

1.  Aerosol therapy with colistin methanesulfonate: a biopharmaceutical issue illustrated in rats.

Authors:  Sandrine Marchand; Patrice Gobin; Julien Brillault; Sara Baptista; Christophe Adier; Jean-Christophe Olivier; Olivier Mimoz; William Couet
Journal:  Antimicrob Agents Chemother       Date:  2010-06-14       Impact factor: 5.191

Review 2.  Dosing of colistin-back to basic PK/PD.

Authors:  Phillip J Bergen; Jian Li; Roger L Nation
Journal:  Curr Opin Pharmacol       Date:  2011-08-09       Impact factor: 5.547

3.  Cellular Uptake and Localization of Polymyxins in Renal Tubular Cells Using Rationally Designed Fluorescent Probes.

Authors:  Bo Yun; Mohammad A K Azad; Cameron J Nowell; Roger L Nation; Philip E Thompson; Kade D Roberts; Tony Velkov; Jian Li
Journal:  Antimicrob Agents Chemother       Date:  2015-09-21       Impact factor: 5.191

4.  Human oligopeptide transporter 2 (PEPT2) mediates cellular uptake of polymyxins.

Authors:  Xiaoxi Lu; Ting Chan; Chenghao Xu; Ling Zhu; Qi Tony Zhou; Kade D Roberts; Hak-Kim Chan; Jian Li; Fanfan Zhou
Journal:  J Antimicrob Chemother       Date:  2015-10-22       Impact factor: 5.790

5.  Heteroresistance to colistin in multidrug-resistant Acinetobacter baumannii.

Authors:  Jian Li; Craig R Rayner; Roger L Nation; Roxanne J Owen; Denis Spelman; Kar Eng Tan; Lisa Liolios
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

6.  Colistin methanesulfonate is an inactive prodrug of colistin against Pseudomonas aeruginosa.

Authors:  Phillip J Bergen; Jian Li; Craig R Rayner; Roger L Nation
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

Review 7.  Polymyxins revisited.

Authors:  David Landman; Claudiu Georgescu; Don Antonio Martin; John Quale
Journal:  Clin Microbiol Rev       Date:  2008-07       Impact factor: 26.132

8.  Pharmacokinetics of four different brands of colistimethate and formed colistin in rats.

Authors:  Hui He; Ji-Chang Li; Roger L Nation; Jovan Jacob; Gong Chen; Hee Ji Lee; Brian T Tsuji; Philip E Thompson; Kade Roberts; Tony Velkov; Jian Li
Journal:  J Antimicrob Chemother       Date:  2013-06-07       Impact factor: 5.790

Review 9.  Rescuing the Last-Line Polymyxins: Achievements and Challenges.

Authors:  Sue C Nang; Mohammad A K Azad; Tony Velkov; Qi Tony Zhou; Jian Li
Journal:  Pharmacol Rev       Date:  2021-04       Impact factor: 25.468

10.  Antimicrobial Activity and Toxicity of the Major Lipopeptide Components of Polymyxin B and Colistin: Last-line Antibiotics against Multidrug-Resistant Gram-negative Bacteria.

Authors:  Kade D Roberts; Mohammad A K Azad; Jiping Wang; Andrew S Horne; Philip E Thompson; Roger L Nation; Tony Velkov; Jian Li
Journal:  ACS Infect Dis       Date:  2015-09-04       Impact factor: 5.084
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.